Presentation - Phase 1 Top-Line Results
Released
Released
Announcement PDF
ASX: PAA
Phase 1 MEND Study Top-Line Results
February 2024
Dr Michael Thurn
Disclaimer
This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by PharmAust Limited (ASX: PAA) (the “Company”). It does not purport to
contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of
the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this
presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent
decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute
discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this
presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations
Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or
similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in
isolation as a basis to invest in the Company.
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and
prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The
performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that
any particular rate of return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended,
recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results,
performance or achievements will be as expected, planned or intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as
defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of
any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from
registration including an exemption for qualified institutional buyers.
2
Phase 1 MEND Study Top-Line Results
Phase 1
Executive Summary
Positive Phase 1 study results showing monepantel has an excellent safety profile and the ability to slow the
progression of MND/ALS
Highlights
3
Primary Objectives
Excellent safety and tolerability profile
Preliminary efficacy data
Slows the rate of progression by 58% (Cohort 2
High Dose)
Blood Brain Barrier
Monepantel and its active metabolite, MPL
Sulphone, and is detectable in cerebrospinal fluid
Competitive Advantage
Superior safety, tolerability and preliminary
efficacy profile to leading FDA approved drug
Relyvrio®
Survival
May prolong a patient’s life expectancy by 13.556.5 months
Phase 2/3 Dose
Optimal dose selected for pivotal Phase 2/3
clinical study
Phase 1 MEND Study Top-Line Results
Phase 1
Study Design
PATIENT POPULATION:
11 Men, 1 Woman
• Adults with Familial or Sporadic ALS/MND
• 1st symptoms occurred < 3 years prior to screening
• Adequate bone marrow reserve, renal & liver
function
• Seated Slow Vital Capacity ≥ 50% of predicted value
• Median Age: 63.5 (42–78) years
LOCATIONS:
Two Centres in Australia
• Calvary Hospital Bethlehem, Melbourne
• Macquarie University, Sydney
4
INTERVENTION:
12 patients randomised
Open label, 24 hour escalating single dose PK study,
followed by 4-week repeated escalating dose study
Treatment continued until dose escalation or End of
Dosing
• Cohort 1: 2 and 6 mg/kg/day dose levels
• Cohort 2: 4 and 10 mg/kg/day dose levels
STUDY OBJECTIVES:
• Tolerability and safety of monepantel with a goal of
defining a maximally tolerated dose (MTD)
• Pharmacokinetics of monepantel and its metabolite
monepantel sulfone (MPLS) in plasma and
cerebrospinal fluid (CSF)
• Preliminary efficacy (ALSFRS-R)
PRIMARY & EXPOLORATORY OUTCOMES:
• Safety and tolerability
• Pharmacokinetic (MPL and its metabolite MPL sulfone in plasma and CSF) and pharmacodynamic (p-RPS6KB1
and p-EIF4EBP1 peripheral blood mononuclear cells)
• ALS Functional Rating Scale–Revised, ALS Quality of Life Questionnaire, Edinburgh Cognitive and Behavioural ALS
Screen, slow vital capacity and biomarkers (serum neurofilament /light chain, CSF neurofilament/light chain and
urinary p75 levels)
Phase 1 MEND Study Top-Line Results
Phase 1
Safety and Tolerability Summary
No deaths, no Serious Adverse Events related to treatment and a very low incidence of Adverse Events
Incidence of Adverse Event n
Dose 1 (2 mg/kg)
Dose 2 (4 mg/kg)
Dose 3 (6 mg/kg)
Dose 4 (10 mg/kg)
Total
Adverse Events
29
6
12
9
56
Related to Treatment
2
1
-
-
3
• Only 3 Adverse Events (mild in severity) possibly related to treatment
• Raised liver enzymes
• Increased hair growth
• Constipation
• No deaths
• No patients withdrew or were discontinued from the study
• One Serious Adverse Event (SAE) reported that was unrelated to treatment
• 1 patient (Dose Level 3 – 6 mg/kg) - hospitalised for Intestinal dilatation and Pneumonia
5
Phase 1 MEND Study Top-Line Results
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Scale – Revised (ALSFRS-R)
ALSFRS-R is a predictor of survival time in ALS patients.1 The speed at which ALS progresses, measured by the rate of
decline in a patient’s ALSFRS-R score over time, can be used to confidently predict disease prognosis.
AMX00352 – 25% Slower Decline in ALSFRS-R
ALSFRS-R Domains Assessed
Bulbar
• Speech
• Salivation
• Swallowing
• Dyspnea
• Orthopnea
• Respiratory
insufficiency
Fine Motor
Gross Motor
• Turning in bed
• Walking
• Climbing Stairs
• Handwriting
• Cutting food
• Dressing & hygiene
ALSFRS-R Score
Respiratory
Each task is rated on a five-point scale from 0 = can't do, to 4 =
normal ability. Individual item scores are summed to produce a
reported score of between 0=worst and 48=best.
Slowing the decline
in ALSFRS-R by
16.5%
=
4-5 months
median
survival3
1Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14(30):3185-3200
6
2FDA Briefing Document 2022 NDA# 216660 Drug Name: AMX0035/ sodium phenylbutyrate (PB) and taurursodiol (TURSO) Applicant: Amylyx Pharmaceuticals, Inc.
3Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):84-98
Phase 1 MEND Study Top-Line Results
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Scale – Revised (ALSFRS-R)
There were no significant differences in ALSFRS-R scores between predose and end of treatment for all 12 patients
Cohort 1, and Cohort 2 suggesting that treatment with monepantel over 8 – 12 months slowed the rate of disease
progression
Rate of Decline of ALSFRS-R From Predose
Predose
End of
Treatment
48
Statistic
Cohort 1
Cohort 2
Total
n
7
6
12
Mean +/- SD
36.7 +/- 6.10
40.5 +/- 2.43
38.5 +/- 4.99
Median
35.0
41.5
41.0
Min, Max
28, 44
37, 43
28, 44
n
6
6
12
Mean +/- SD
23.7 +/- 12.18
34.7 +/- 10.05
29.2 +/- 12.10
Median
26
37.5
34.5
8
Min, Max
7, 37
15, 43
7, 43
4
p-value
0.4065
0.8794
0.7789
44
40
No Significant difference
36
ALSFRS-R Score
Visit
Rate of Decline of ALSFRS-R
32
28
24
20
No Significant difference
16
Cohort 1
12
Cohort 2
0
0
1
2
3
4
5
6
7
8
9
10
11
12
Months of Treatment
No significant difference between Predose and End of Treatment
7
Phase 1 MEND Study Top-Line Results
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Scale – Revised (ALSFRS-R)
Treatment with monepantel for up to 12 months slowed the progression of MND/ALS in all 12 patients by 39% when
compared to matched controls from the PRO-ACT database1
ALSFRS-R Domains Assessed
MPL – 39% Slower Decline in ALSFRS-R
Bulbar
• Speech
• Salivation
• Swallowing
• Dyspnea
• Orthopnea
• Respiratory
insufficiency
Fine Motor
Gross Motor
• Turning in bed
• Walking
• Climbing Stairs
Points per month
ALSFRS-R Score
Respiratory
Monepantel
• Handwriting
• Cutting food
• Dressing & hygiene
Each task is rated on a five-point scale from 0 = can't do, to 4 =
normal ability. Individual item scores are summed to produce a
reported score of between 0=worst and 48=best.
-0.74
PRO-ACT
Matched Controls
-1.22
Monepantel
PRO-ACT
Matched Controls
Months of Treatment
The PRO-ACT database is the largest publicly available repository of merged ALS
clinical study data. Data were pooled from 16 completed Phase 2/3 ALS clinical
studies and one observational study. Over 8 million de-identified longitudinally
collected data points from more than 8,600 persons with ALS, including
demographics, family histories, and longitudinal clinical and laboratory data.
1Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov
8
4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
Phase 1 MEND Study Top-Line Results
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Scale – Revised (ALSFRS-R)
Dose response observed between Cohort 1 and 2. Rate of disease progression in Cohort 2 was slowed by an impressive
58% compared to the PRO-ACT database matched controls
FDA Timeframe for accelerated approval
Cohort 1
-0.83 points per month
23% Slower Decline in ALSFRS-R
Monepantel
ALSFRS-R Score
PRO-ACT
Matched Controls
FDA Timeframe for accelerated approval
Cohort 2
-0.60 points per month
58% Slower Decline in ALSFRS-R
Monepantel
PRO-ACT
Matched Controls
9
Months of Treatment
Phase 1 MEND Study Top-Line Results
Phase 1
Exploratory Endpoints
No significant difference in ALS Quality of Life Questionnaire, Edinburgh Cognitive and Behavioural ALS Screen,
and Slow Vital Capacity between predose and end of treatment
ALSSQOL-R
Quality of Life Questionnaire
Edinburgh Cognitive and Behavioural
ALS Screen
10
9
5
Cohort 1
4
Cohort 2
3
2
1
Predose
End of Treatment
50-item disease-specific questionnaire that is
completed by the individual with ALS. Each item is
rated on a 10-point Likert scale, with 0 being the
least desirable situation and 10 being the most
desirable. The instrument produces a single-item
QoL score and six domain scores (negative emotion,
interaction with people and environment, intimacy,
religiosity, physical symptoms, and bulbar function).
1
0
6.0
120
5.0
4.0
80
Litres
6
0
140
100
7
ECAS Score
ALSSQOL-R Score
8
Slow Vital Capacity
Cohort 1
Cohort 2
60
3.0
2.0
40
20
1.0
0
0.0
Predose
Cohort 1
Cohort 2
End of Treatment
A clinical cognitive screening tool for cognitive and
behavioural abnormalities in ALS. Includes
assessment of fluency, executive functions,
language, memory, and visuospatial functions. The
total score is 136 points.
Predose
End of Treatment
A lung function test that measures how much air
can be exhaled out in a relaxed manner, similar to a
gentle sigh, until your lungs are completely empty.
Phase 1 MEND Study Top-Line Results
Phase 1
Exploratory Biomarkers
No significant difference in biomarkers serum neurofilament /light chain (NfL) and urinary p75ECD levels
between pre-dose and end of treatment
Neurofilament Light Chain
Serum
Neurofilament Light Chain
Cerebrospinal Fluid
100
14
10000
90
12
8000
60
NfL (pg/ml)
NfL (pg/ml)
70
50
40
30
Cohort 1
20
Cohort 2
Patient 01-11
6000
Patient 01-07
4000
Patient 01-09
2000
Predose
End of Treatment
8
6
Cohort 1
4
Cohort 2
2
10
0
10
(ng p75ECD/mg CR)
80
0
Urinary p75ECD/Creatinine
Predose
End of Treatment
0
Predose
End of Treatment
Marked decreased NfL cerebrospinal fluid (CSF) levels in all 3 patients where CSF samples were available
Urinary p75ECD levels remained stable in Cohort 2 patients. Urinary p75ECD levels increase on average 0.19
ng/mg of creatinine per month as the disease progresses
11
Phase 1 MEND Study Top-Line Results
Phase 1
Pharmacokinetics and Target Engagement (mTOR Pathway)
Cohort 1 (2 & 6 mg/kg)
Cohort 2 (4 & 10 mg/kg)
Pharmacokinetics
Concentrations of MPL Sulphone, the active metabolite of MPL, increased somewhat proportionally with higher doses of MPL.
MPL and MPLS was found in the cerebrospinal fluid.
Target Engagement (mTOR Pathway)
Target engagement of the mTOR pathway (p-EIF4EBP1 and p-RPS6KB1) in peripheral mononuclear blood cells was confirmed
at all dose levels
12
Phase 1 MEND Study Top-Line Results
Phase 1
Comparison to Leading FDA-Approved Product
Monepantel displays a superior safety, tolerability and preliminary efficacy profile to the leading FDA
approved drug Relyvrio®
Estimated Additional Life Expectancy for MPL
Estimated rate
of ALSFRS-R
Decline (points
per month)
Slowing in
ALSFRS-R
Decline (%)
Slope Change
from PRO-ACT
matched
controls
Additional Life
Expectancy
(months)
Combined Cohort 1 & 2
-0.74
39%
0.48
13.5 – 56.5
Cohort 1 (Low Dose)
-0.83
23%
0.24
Cohort 2 (High Dose)
-0.60
58%
0.83
Relyvrio®
-1.24
25%
8–9
Treatment with monepantel may prolong a patient’s life
expectancy by 13.5-56.5 months
Median Survival Table1
ALSFRS-R
Slope
(points per
month)
Median
Survival
(Months)
Increase in
Life
Expectancy
(Months)
<-0.25
78.5
56.5
-0.25-0.45
44.0
22.0
-0.50-0.99
35.5
13.5
>-1.0
22.0
1Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015 Jun;262(6):1447-54. doi: 10.1007/s00415-015-7731-6. Epub 2015 Apr 11. PMID: 25860344; PMCID: PMC4469087.
13
Phase 1 MEND Study Top-Line Results
Phase 1
Conclusion
Positive Phase 1 study results showing monepantel has an excellent safety profile and the ability to slow the
progression of MND/ALS
14
Primary Objectives
Excellent safety and tolerability profile
Preliminary efficacy data
Elows the rate of progression by 58% (Cohort 2
High Dose)
Blood Brain Barrier
Monepantel and its active metabolite, MPLS, and
is detectable in cerebrospinal fluid
Competitive Advantage
superior safety, tolerability and preliminary
efficacy profile to leading FDA approved drug
Relyvrio®
Survival
May prolong a patient’s life expectancy by 13.556.5 months
Next Steps
Moving forward with pivotal Phase 2/3 clinical
study
Phase 1 MEND Study Top-Line Results
Thank you
15
Phase 1 MEND Study Top-Line Results
ASX: PAA
For more information, please contact
Matthew Baker, Corporate Advisor, Blue Ocean Equities
+61 (0) 418 830 064, matthewbaker@boeq.com.au
Matthew Wright, Investor Relations, NWR Communications
+61 (0) 451 896 420, matt@nwrcommunications.com.au
Registered Address:
Suite 116, 1 Kyle Way, Claremont WA 6010
Australia
Phone: +61 (8) 9202 6814
Email: investorenquiries@pharmaust.com
Share your feedback
Discover